ANeuroTech team,
decades of exerience in clinical drug evelopment

About us

Our Team is committed to the invention of new medicines to treat people suffering from depression and to the creation of substantial value for investors and partners.

We have comprehensive experience in the science and business of CNS drug discovery and development up till Market Authorization Approval (MAA).

Management

Founding CEO and Chief Scientific Officer

Erik Buntinx, MD-Psychiatrist, Inventor

Experienced Chief Executive Officer with a demonstrated history of working in the pharmaceuticals industry
Inventor of multiple worldwide granted patents in the field of neurosciences
Veteran Principal Investigator in key drug development programs
Senior Clinical Advisor on major CNS drug development programs

COO

Lars Bastiaanse
PhD

Former Compound Development Team Leader at J&J

Chief CMC

Lieven Baert
PharmD, PhD, MBA

Previous Senior research fellow / Vice President early development and innovation, Johnson & Johnson

Chief Clinical Pharmacology

Didier de Chaffoy de Courcelles, PhD

Former Senior Vice-President Discovery and Early Development, Janssen

Chief Non Clinical Development

Arthur Noach
PhD, PharmD

Non-Clinical Expert / Senior Consultant at Venn LS

Scientific Advisory Board

Prof. Charles B. Nemeroff, Chair

MD, PhD
University of Texas

Prof. Dr. Alan Schatzberg

MD
Stanford University

Prof. Philip Harvey

PhD
University of Miami

Dr. Tom Laughren

MD
Former Head Psychiatric Products FDA


The Status of ANT01 and ANeuroTech

23 February 2022
FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD).

Read more

Scroll to Top